Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

BTIG's Kambiz Yazdi raised their price target on Zevra Therapeutics (NASDAQ: ZVRA) by 17.4% from $23 to $27 on 2026/06/09. The analyst reiterated their Strong Buy rating on the stock.

Raising their price target, Yazdi referenced Zevra Therapeutics' announcement of submission of U.S. Patent No. 11,707,456 to FDA for Orange Book listing for Miplyffa, with nominal expiry in 2041.

The analyst explained that U.S. Patent No. 11,707,456 appears to cover a defined arimoclomol citrate composition with specified purity and impurity parameters.

If listed, Yazdi continued, the patent would add another layer to Miplyffa's Intellectual Property portfolioi, which already includes Orange Book-listed patents, orphan drug exclusivity to 2031, and a pending patent term extension on U.S. Patent No. 11,045,460 that could extend the term of that patent to 2034.